secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0001140361-22-044598
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics terminates San Diego office lease; consolidates R&D to Cambridge, MA
--------------------------------------------------------------------------------

- Entered lease termination agreement for 5,193 sq ft office at 10355 Science Center Drive, San Diego.
- Lease will terminate if Landlord re-lets premises by Jan 15, 2023; effective Feb 28, 2023.
- Termination fee of $100,000 payable in two installments; otherwise lease expires June 2027.
- Termination aligns with previously announced decision in Q2 2022 to consolidate R&D in Cambridge, MA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036122044598/0001140361-22-044598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036122044598/brhc10045139_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-044598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer